Lung Cancer Trials Ask AI to find trials
Active Not RecruitingNot applicableNCT05853887
Official study title

Liquid Biopsy Based NGS in Newly Diagnosed NSCLC

Study summary

This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.

Ask AI to explain this study
Start here

Key things to know

Main goalHealth Services Research

This describes the study’s primary purpose.

What is being studiediNUDGE

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 11, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Not applicable

Interventional

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Charu Aggarwal

Study sponsor

01
Study overview

What this study is about

Purpose
Health Services Research
Study type
Interventional
Phase
Not applicable
Sponsor
Charu Aggarwal
Interventions being studied
Behavioral: iNUDGE
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Treatment approach
Supportive or behavioral care→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants with a histological, or cytological diagnosis of metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) who have not yet received systemic treatment for metastatic disease.
  • Participants must be seen at Lancaster General Health (LGH), Penn Presbyterian Medical Center (PPMC), Penn Medicine Cherry Hill (PMCH), Penn Medicine Princeton Health (PMPH), Penn Medicine Voorhees (PMV) or Penn Medicine Washington Township (PMWT) for mNSq NSCLC.
Reasons someone may not be able to joinExclusion criteria
  • Participants with incomplete staging information.
  • Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Penn Medicine Cherry HillCherry Hill, New Jersey
  • Penn Medicine Princeton HealthPlainsboro, New Jersey
  • Penn Medicine Washington TownshipSewell, New Jersey
  • Penn Medicine VoorheesVoorhees Township, New Jersey
  • Penn Medicine Lancaster General HealthLancaster, Pennsylvania
  • Penn Presbyterian Medical CenterPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 11, 2026. Always confirm current availability with the study team.

View original record ↗